Telemedicine for Hyperkinetic Movement Disorders

Srinivasan, Ragini; Ben‐Pazi, Hilla; Dekker, Marieke; Cubo, Esther; Bloem, B.R.; Moukheiber, Emile; González‐Santos, Josefa; Guttman, Mark

doi:10.5334/tohm.534

Cited by 24 publications

(30 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is traditionally subdivided into synchronous (interactive video connection) and asynchronous telemedicine (store-and-forward transmission of medical images and/or data). 46 The epidemic has already driven the rapid innovation and implementation of these systems for the delivery of urgent and ongoing health care. A major benefit of expanding telehealth with no restrictions would reduce person-to-person contact between health service providers and COVID-19 and reduce the risk of exposure of noninfected but susceptible patients in waiting room areas.…”

Section: Telemedicinementioning

confidence: 99%

“…47 Simple communication methods such as e-mail and text messaging should be used more extensively to provide general support, 48 especially as a suitable modality for lower income regions or for areas lacking the bandwidth and continuous connectivity to perform synchronous telemedicine. 46 Another benefit of asynchronous telemedicine is that videos can be obtained for patients experiencing paroxysmal movement disorders. Nevertheless, for many people with PD, videoconferencing is widely accessible and can provide clinicians with useful motor and nonmotor assessments of patient symptoms 49,50 and is also approved of by patients.…”

Section: Telemedicinementioning

confidence: 99%

See 1 more Smart Citation

Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID‐19 Experience

Fasano

Antonini

Katzenschlager

et al. 2020

Movement Disord Clin Pract

129

View full text Add to dashboard Cite

Background Although the COVID‐19 pandemic is affecting a relatively small proportion of the global population, its effects have already reached everyone. The pandemic has the potential to differentially disadvantage chronically ill patients, including those with Parkinson's disease (PD). The first health care reaction has been to limit access to clinics and neurology wards to preserve fragile patients with PD from being infected. In some regions, the shortage of medical staff has also forced movement disorders neurologists to provide care for patients with COVID‐19. Objective To share the experience of various movement disorder neurologists operating in different world regions and provide a common approach to patients with PD, with a focus on those already on advanced therapies, which may serve as guidance in the current pandemic and for emergency situations that we may face in the future. Conclusion Most of us were unprepared to deal with this condition given that in many health care systems, telemedicine has been only marginally available or only limited to email or telephone contacts. In addition, to ensure sufficient access to intensive care unit beds, most elective procedures (including deep brain stimulation or the initiation of infusion therapies) have been postponed. We all hope there will soon be a time when we will return to more regular hospital schedules. However, we should consider this crisis as an opportunity to change our approach and encourage our hospitals and health care systems to facilitate the remote management of chronic neurological patients, including those with advanced PD.

show abstract

Section: Telemedicinementioning

confidence: 99%

Section: Telemedicinementioning

confidence: 99%

Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID‐19 Experience

Fasano

Antonini

Katzenschlager

et al. 2020

Movement Disord Clin Pract

129

View full text Add to dashboard Cite

show abstract

“…Nevertheless, there are still limitations to telemedicine. In a recent online survey with 781 PD patients who participated in telemedicine, the main concerns were lack of hands-on care, lack of intimacy and technical difficulties [25] A consistent barrier in providing virtual care is poor internet connectivity and video quality issues, which is especially limiting in less developed countries [24,26]. To bypass this problem, asynchronous videos can be used to capture PD symptoms and sent to neurologists via email, which is more widely accessible [26].…”

Section: The Transition To Virtual Pd Patient Carementioning

confidence: 99%

Potential impact and challenges associated with Parkinson’s disease patient care amidst the COVID-19 global pandemic

Elbeddini

Tayefehchamani

et al. 2020

J Clin Mov Disord

View full text Add to dashboard Cite

Background: COVID-19 has made itself known to health care providers and families across the world in a matter of months. While primarily a respiratory disorder, it has also been shown to cause neurological symptoms, which can be a concern for Parkinson's disease (PD) patients. Although PD is not as common as other conditions such as cardiovascular diseases, it affects millions of patients around the world whose care has been affected by the global pandemic. Objectives: The aim of this review is to provide insight into the direct and indirect associations between COVID-19 and PD patient care. Results: Potential direct effects of COVID-19 include possible neurodegeneration, concerns of symptom selfmanagement with over-the-counter (OTC) products and ICU challenges that can arise in PD patients. In addition, a subset of PD patients may be at higher risk of severe COVID-19 infection. The indirect effects of the pandemic are associated with the social distancing measures and disruptions in health care systems and PD clinical trials, which may negatively affect PD patients' mental wellbeing and create barriers in controlling their PD symptoms. On a more positive note, telemedical care is quickly emerging as a primary communication tool for virtual patient care. However, further research should be conducted to examine the applicability of telemedicine across the entire PD population, such as those with more severe symptoms living in less developed areas. With all the uncertainty during this time, it is hopeful to hear many promising COVID-19 treatments being researched, one of them being a PD drug therapy, amantadine. Conclusion: Hopefully, we can consider this pandemic an opportunity to strengthen the PD community and learn more about the impact of the SARS-COV-2 virus. This review provides an overview of the interaction between COVID-19 and PD patients and future investigational retrospective studies are suggested to validate the observations.

show abstract

“…To date, most studies in this field have either evaluated its feasibility in the provision of followup services to patients with known diagnoses or examined its usefulness in the administration of standardized rating scales. [7][8][9][14][15][16][17] Telemedicine studies on new referrals to general neurology clinics report possible reduced diagnostic certainty and increased diagnostic testing. 18,19 Telemedicine could compromise diagnostic abilities on many levels.…”

Section: Is Diagnostic Ability Compromised By Telemedicine?mentioning

confidence: 99%